Literature DB >> 6922088

Modulation of classical C3 convertase of complement by tear lactoferrin.

A Kijlstra, S H Jeurissen.   

Abstract

Lactoferrin isolated fom normal human tears was shown to inhibit the complement-mediated lysis of antibody-coated red cells. The anti-complementary effect of lactoferrin on serum complement could be reversed by adding Fe3+ but not by Mg++ or Ca++. Lactoferrin did not inhibit the formation of EAC14 but markedly blocked the assembly of the EAC142 enzyme. Once the C3 convertase was formed lactoferrin did not affect the function of the enzyme and only had a minor effect on the intrinsic decay of C2 from the convertase. Inhibition of the C3 convertase formation was not seen by preincubating EAC14 intermediates with lactoferrin, but only occurred when lactoferrin and C2 were incubated together with EAC14 cells. Our findings suggest that lactoferrin may play an anti-inflammatory role by modulating activation of the complement system.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6922088      PMCID: PMC1555462     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  Association of lactoferrin with other proteins, as demonstrated by changes in electrophoretic mobility.

Authors:  A Hekman
Journal:  Biochim Biophys Acta       Date:  1971-12-28

2.  Immunological and electrophoretic studies of human tear proteins.

Authors:  A M Gachon; P Verrelle; G Betail; B Dastugue
Journal:  Exp Eye Res       Date:  1979-11       Impact factor: 3.467

3.  Immunoglobulins in human tears.

Authors:  J M Little; Y M Centifanto; H E Kaufman
Journal:  Am J Ophthalmol       Date:  1969-11       Impact factor: 5.258

4.  Inhibition of hemolytic complement activity by lactoferrin in tears.

Authors:  R Veerhuis; A Kijlstra
Journal:  Exp Eye Res       Date:  1982-02       Impact factor: 3.467

5.  Quantitative determinations of complement components and immunoglobulins in tears and aqueous humor.

Authors:  J W Chandler; R Leder; H E Kaufman; J R Caldwell
Journal:  Invest Ophthalmol       Date:  1974-02

6.  The effect of an anticomplementary factor on normal human tears.

Authors:  A Kijlstra; R Veerhuis
Journal:  Am J Ophthalmol       Date:  1981-07       Impact factor: 5.258

7.  Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme.

Authors:  L Halbwachs; M Leveillé; P Lesavre; S Wattel; J Leibowitch
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

8.  Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein.

Authors:  M R Daha; L A van Es
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

9.  Lactoferrin, an iron-binding protein in neutrophilic leukocytes.

Authors:  P L Masson; J F Heremans; E Schonne
Journal:  J Exp Med       Date:  1969-09-01       Impact factor: 14.307

10.  Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement.

Authors:  H J Müller-Eberhard; M J Polley; M A Calcott
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

View more
  20 in total

1.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

2.  The protein structure of recombinant human lactoferrin produced in the milk of transgenic cows closely matches the structure of human milk-derived lactoferrin.

Authors:  Ellen A J Thomassen; Harrie A van Veen; Patrick H C van Berkel; Jan H Nuijens; Jan Pieter Abrahams
Journal:  Transgenic Res       Date:  2005-08       Impact factor: 2.788

3.  Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants.

Authors:  P H van Berkel; H A van Veen; M E Geerts; H A de Boer; J H Nuijens
Journal:  Biochem J       Date:  1996-10-01       Impact factor: 3.857

4.  Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.

Authors:  F Kievits; A Kijlstra
Journal:  Immunology       Date:  1985-03       Impact factor: 7.397

5.  Lactotransferrin immunocytochemistry in Alzheimer and normal human brain.

Authors:  T Kawamata; I Tooyama; T Yamada; D G Walker; P L McGeer
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

6.  Expression of human lactoferrin in milk of transgenic mice.

Authors:  G J Platenburg; E P Kootwijk; P M Kooiman; S L Woloshuk; J H Nuijens; P J Krimpenfort; F R Pieper; H A de Boer; R Strijker
Journal:  Transgenic Res       Date:  1994-03       Impact factor: 2.788

7.  Activation of the classical pathway of complement by binding of bovine lactoferrin to unencapsulated Streptococcus agalactiae.

Authors:  P Rainard
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

8.  Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo.

Authors:  M Machnicki; M Zimecki; T Zagulski
Journal:  Int J Exp Pathol       Date:  1993-10       Impact factor: 1.925

9.  Plasma lactoferrin in patients with neutropenia.

Authors:  R D Brown; E Yuen; K A Rickard; P C Vincent; G Young; H Kronenberg
Journal:  Blut       Date:  1986-05

10.  Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury.

Authors:  P A Ward; G O Till; R Kunkel; C Beauchamp
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.